Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada
Crossref DOI link: https://doi.org/10.1186/s12916-025-03928-z
Published Online: 2025-02-21
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bugden, Samara
Mital, Shweta
Nguyen, Hai V.
Text and Data Mining valid from 2025-02-21
Version of Record valid from 2025-02-21
Article History
Received: 6 September 2024
Accepted: 6 February 2025
First Online: 21 February 2025
Declarations
:
: Not applicable.
: The authors declare no competing interests.